Abstract:Background The bromodomain and extra-terminal domain (BET) family of proteins, especially BRD4 play an important role in epigenetic regulation, and are essential for cell survival and also are promising anticancer targets. This study aims to analyze the effect of BRD4 on the cell growth and progression of pancreatic cancer and novel mechanisms involved. Methods Expression of BRD4 in pancreatic cancer and paired adjacent noncancerous tissues from 76 patients was analyzed by western blotting, immunohistochemistry, and real time PCR. Its correlation with the clinicopathological characteristics and prognosis of pancreatic cancer patients was analyzed. The effects of BRD4 on the cell proliferation were detected by colony formation assay and sulforhodamine B assay. Migration and invasion were determined by Transwell assays, and the effect of BRD4 on subcutaneous tumor formation was verified in nude mice. Cell cycle analysis was detected by flow cytometry. The potential downstream targets of BRD4 and related molecular mechanisms were clarified by RNA sequencing, chromatin immunoprecipitation and dual luciferase reporter assay. Results BRD4 was overexpressed in pancreatic cancer. Biological results showed that BRD4 functioned as tumor promoter, facilitated cell proliferation, migration and invasion in vitro and in vivo. Further, caveolin-2 was selected as the downstream gene of BRD4 by RNA sequencing. Caveolin-2 overexpression can partially reverse the decreased cell growth ability caused by BRD4 knockdown, but did not affect cell migration and invasion. Chromatin immunoprecipitation assay and dual luciferase reporter assay revealed BRD4 could bind to the promoter region of caveolin-2 and upregulate caveolin-2 expression. Clinical data further indicated a positive correlation between BRD4 and caveolin-2 expression. BRD4 (high)/caveolin-2 (high) correlated with shorter overall survival of patients with pancreatic cancer. Multivariate analysis revealed that both BRD4 and caveolin-2 were independent factors. Conclusions Our findings reveal the oncogenic effects of BRD4 in pancreatic cancer and elucidate a possible mechanism by which BRD4 and caveolin-2 act to enhance cell growth. Targeting the BRD4-caveolin-2 interaction by development of BET inhibitors will be a therapeutic strategy for pancreatic cancer.

BRD4 Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Brd4 Induces Cell Migration and Invasion in Hcc Cells Through Mmp-2 and Mmp-9 Activation Mediated by the Sonic Hedgehog Signaling Pathway

High level of BRD4 promotes non-small cell lung cancer progression

BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial–mesenchymal transition via upregulating ID2

Bmp4 Enhances Hepatocellular Carcinoma Proliferation by Promoting Cell Cycle Progression Via Id2/Cdkn1b Signaling

Caveolin-2 is Regulated by BRD4 and Contributes to Cell Growth in Pancreatic Cancer

BRD4 Promotes the Stemness of Gastric Cancer Cells Via Attenuating Mir-216A-3p-mediated Inhibition of Wnt/β-catenin Signaling.

Overexpression of BRD4 in gastric cancer and its clinical significance as a novel therapeutic target

BRD8, Which is Negatively Regulated by Mir-876-3p, Promotes the Proliferation and Apoptosis Resistance of Hepatocellular Carcinoma Cells Via KAT5

BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma

KDM5C-mediated recruitment of BRD4 to chromatin regulates enhancer activation and BET inhibitor sensitivity

Co-overexpression of BRD4 and CDK7 Promotes Cell Proliferation and Predicts Poor Prognosis in HCC

BTB/POZ domain-containing protein 7: epithelial-mesenchymal transition promoter and prognostic biomarker of hepatocellular carcinoma.

Data from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

BRD4-binding Enhancer Promotes CRC Progression by Interacting with YY1 to Activate the Wnt Pathway Through Upregulation of TCF7L2.

B7-H3 is Regulated by BRD4 and Promotes TLR4 Expression in Pancreatic Ductal Adenocarcinoma

BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.

Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway

Data from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Bromodomain-containing Protein 9 Promotes the Growth and Metastasis of Human Hepatocellular Carcinoma by Activating the TUFT1/AKT Pathway

ERBB4 acts as a suppressor in the development of hepatocellular carcinoma.